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Abstract
Background: Comparing outcomes between hospitals requires consideration of patient factors that could account
for any observed differences. Adjusting for comorbid conditions is common when studying outcomes following
cancer surgery, and a commonly used measure is the Charlson comorbidity index. Other measures of patient health
include the ECOG performance status and the ASA physical status score. This study aimed to ascertain how frequently
ECOG and ASA scores are recorded in population-based administrative data collections in New South Wales, Australia
and to assess the contribution each makes in addition to the Charlson comorbidity index in risk adjustment models for
comparative assessment of colorectal cancer surgery outcomes between hospitals.
Methods: We used linked administrative data to identify 6964 patients receiving surgery for colorectal cancer in 2007
and 2008. We summarised the frequency of missing data for Charlson comorbidity index, ECOG and ASA scores, and
compared patient characteristics between those with and without these measures. The performance of ASA and ECOG
in risk adjustment models that also included Charlson index was assessed for three binary outcomes: 12-month
mortality, extended length of stay and 28-day readmission. Patient outcomes were compared between hospital
peer groups using multilevel logistic regression analysis.
Results: The Charlson comorbidity index could be derived for all patients, ASA score was recorded for 78 % of
patients and ECOG performance status recorded for only 24 % of eligible patients. Including ASA or ECOG
improved the predictive ability of models, but there was no consistently best combination. The addition of ASA
or ECOG did not substantially change parameter estimates for hospital peer group after adjusting for Charlson
comorbidity index.
Conclusions: While predictive ability of regression models is maximised by inclusion of one or both of ASA score
and ECOG performance status, there is little to be gained by adding ASA or ECOG to models containing the Charlson
comorbidity index to address confounding. The Charlson comorbidity index has good performance and is an
appropriate measure to use in risk adjustment to compare outcomes between hospitals.
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Background
Comparing outcomes between clinicians, institutions or
area health services requires consideration of potential
confounding factors, such as patient age, health status or
disease severity, that could account for any observed dif-
ferences in outcomes. Risk adjustment is a statistical
technique used to account for variations in outcome that
arise from differences in the characteristics of patients,
so as to provide a fair and more accurate comparison of
health services. Patient age, sex, cancer site and cancer
stage are commonly used in risk adjustment models as
they have high levels of completeness and accuracy in
routinely collected datasets such as cancer registries and
hospital episode collections.
Adjustment for comorbid conditions is common when
studying outcomes following cancer surgery [1]. The
Charlson comorbidity index summarises information
about the presence of a number of medical conditions,
assigns a severity score to each, and sums the severity
scores to create a single measure of comorbidity [2]. Al-
gorithms have been derived to calculate the Charlson co-
morbidity index from hospitalisation records coded
using the Ninth [3, 4] and Tenth [5, 6] Revisions of the
International Classification of Diseases. The Charlson
comorbidity index has been shown to be a good pre-
dictor of both short-term (in hospital and 30-days) and
longer-term (12-month) mortality [7].
Functional status is an additional patient factor that
may explain differences in outcome. One measure of
functional status is the Eastern Cooperative Oncology
Group (ECOG) Performance Status, [8] a score ranging
from 0 (“fully active”) through 3 (”capable of only lim-
ited self-care”) to 5 (“dead”). An alternative measure of
a patient’s general health is the American Society of
Anesthesiologists (ASA) score [9]. This measure of
physical status ranges from 1 for a normal healthy pa-
tient to 5 for a moribund patient who is not expected
to survive surgery and is recorded routinely by anaes-
thetists prior to any surgical procedure. ECOG and
ASA scores are available in some administrative data
collections.
While recent studies have assessed the predictive
capacity of comorbidity and health status measures in
risk adjustment for outcomes of cancer surgery, [10, 11]
they did not consider performance status. A study that
compared comorbidity index, ASA and ECOG perform-
ance status [12] considered each measure separately, and
did not assess the additional effect of health and perform-
ance status over comorbidity. In a recent study comparing
ASA with ECOG, [13] no comparison was made with co-
morbidity index as it was not possible to derive a comor-
bidity index from the available data. Additionally, these
studies used data extracted from patients’ medical records,
not routinely collected data.
Therefore, we conducted this study to assess how fre-
quently the ASA score and ECOG performance status
can be obtained from population-based administrative
data collections in New South Wales, the most populous
state in Australia, and to assess the contributions of
ASA score and ECOG performance status additional to
the Charlson comorbidity index, in comparing outcomes
of colorectal cancer surgery between hospital peer
groups based on risk adjustment models.
Method
Data sources
Our study population comprised all people with an inci-
dent cancer of the colon or rectum registered in NSW,
the most populous state in Australia. We used the first
recorded tumour of the colon or recto-sigmoid junction
(ICD-O-3 codes: C18, C19) or rectum (C20) registered
on the NSW Central Cancer Registry (CCR) between 1
January 2000 and 31 December 2008. The NSW CCR, a
population-based register of all cancers in NSW residents,
receives notifications from public and private hospitals,
departments of radiation oncology, nursing homes, path-
ology laboratories, outpatient departments and day pro-
cedure centres as a statutory requirement.
Cancer notifications were linked to the Admitted
Patients’ Data Collection (APDC), the Clinical Cancer
Registry (ClinCR) and the NSW Registry of Births,
Deaths and Marriages (RBDM). The APDC contains
demographic and episode-related information on all
hospital separations for public and private hospitals in
NSW, [14] while the ClinCR contains clinically-based
information, including the ECOG performance status,
for patients with cancer treated in public facilities
within six area health services [15]. Hospital admissions
with procedures defined as being for curative intent
were used, [15] with these procedures based on clinical
consultation and previously used procedure codes [16, 17].
Where patients had more than one hospital admission with
a procedure of interest, the first admission was used in ana-
lysis. We used hospital records with separations in 2007
and 2008, as this was the period for which clinical cancer
registry data were available. Fact of death was obtained
from the RBDM for the period up to 2010.
Probabilistic data linkage was conducted by the NSW
Centre for Health Record Linkage, and we received only
anonymised data. Ethics approval for the study was
given by the NSW Population and Health Services
Research Ethics Committee (HREC/11/CIPHS/32).
Outcomes
We considered three binary outcomes. Mortality was
assessed at 12 months, measured from date of procedure
until death from any cause. Hospital stay following sur-
gery was measured from the date of procedure until
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separation, accounting for transfers, and categorized
based on exceeding the recommended length of stay for
procedures based on the Australian Refined Diagnostic
Related Group [18]. This allowed for length of stay to be
assessed based on procedure complexity. Readmission
within 28 days was derived from the date of separation
until any subsequent readmission.
Peer group
Peer groups classify similar hospitals based on the number
of separations, primary role and location (metropolitan or
rural). Admitting hospitals were classified into one of six
groups based on NSW Peer Group definitions. [19].
Measures of patient health
We calculated the Charlson comorbidity index using
codes for comorbid conditions recorded during the
index admission in the APDC. We excluded metastatic
cancer from the calculation as in the context of cancer
treatment, this is part of the condition of interest rather
than a comorbidity. Charlson comorbidity indices were
categorised into values of 0, 1 and 2 or more in risk ad-
justment models as very few patients (8 %) had scores of
two or higher.
The ASA score was obtained from the suffix of ICD
procedure codes indicating administration of an anaes-
thetic (see Additional File 1). Possible ASA scores are 1
(normal healthy patient); 2 (mild systemic disease); 3
(severe systemic disease); 4 (severe systemic disease
that is a constant threat to life) or 5 (moribund patient
who is not expected to survive) [9]. We grouped ASA
scores of 4 or 5 in risk adjustment models due to the
sparseness of higher scores.
ECOG performance status was obtained from ClinCR
records. We used the ECOG performance status recorded
closest in time on or before the data of procedure. Possible
ECOG scores are 0 (fully active, no performance restric-
tion); 1 (restricted in physically strenuous activity but am-
bulatory, able to carry out work of a light or sedentary
nature); 2 (ambulatory and capable of all self-care but un-
able to carry out any work activities. Up and about more
than 50 % of waking hours); 3 (capable of only limited
self-care, confined to bed or chair more than 50 % of wak-
ing hours); 4 (Completely disabled, cannot carry out any
self-care. Totally confined to bed or chair) or 5 (dead) [8].
We grouped ECOG performance status of 2 or higher in
risk adjustment models due to the sparseness of higher
scores.
Other patient factors
Extent of tumour spread, obtained from the CCR, sum-
marises the most aggressive extent of the disease based
on diagnostic and therapeutic evidence within four
months of diagnosis [20]. Patient sex, age and emergency
status of admission were obtained from the APDC,
with age calculated at date of procedure. Country of
birth, also obtained from APDC, was classified as Aus-
tralian versus other.
Statistical analysis
Descriptive statistics were used to compare patient charac-
teristics for patients with non-missing values of Charlson
comorbidity index, ASA score and ECOG performance
status. Associations between the three patient health mea-
sures were summarised using Spearman’s rank correlation
coefficients.
Risk adjustment models were constructed using two-level
multilevel logistic regression models to compare the binary
outcome measures across the peer groups, with patients
(level-1) clustered within hospitals (level-2). Random-
intercept models were fitted, with hospital included as a
random effect. Only patients with non-missing values of
Charlson comorbidity index, ASA score and ECOG per-
formance status were used so that risk adjustment models
could be compared on the same group of patients. Hence
we used only records from patients treated in public hos-
pitals. As such, only the four peer groups representing
public hospitals were considered: Principal Referral A,
Principal Referral B, Major Metropolitan and Major Non-
Metropolitan. Major Metropolitan and Non-Metropolitan
peer groups were grouped together due to the low patient
numbers in Major Non-Metropolitan hospitals.
We evaluated the utility of ASA score and ECOG
performance status by fitting all combinations of
these over and above a base model assessing the as-
sociation between hospital peer group and each of
the three study outcomes (12-month mortality, ex-
tended length of stay and readmission within 28 days)
adjusted for patient age, sex, extent of disease, emer-
gency status of admission and Charlson comorbidity
index. Model performance was assessed using
Akaike’s information criterion (AIC), with lower
values indicating a better fitting model. We also cal-
culated the C statistic, summarising the concordance
between observed and predicted events. Concordance
ranges between 0.5 (a model with no predictive abil-
ity) and 1.0 (a model with perfect predictive ability)
[21]. Finally, we compared estimated logistic regres-
sion parameters for hospital type to assess the extent
of confounding explained by the inclusion of ASA
score and ECOG performance status.
Data processing and descriptive analyses were con-
ducted using Version 9.3 of the SAS System for Windows
(Cary, NC, USA), with multilevel logistic modelling con-
ducted using adaptive quadrature via the xtmelogit com-
mand of Stata Version 12 for Windows (College Station,
TX: StataCorp LP).
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Results
We obtained records from 6,964 individuals who were
operated in 2007 or 2008, and their characteristics are
presented in Table 1. The Charlson comorbidity index
could be calculated for the entire sample, as it is based
on comorbid conditions recorded during the index ad-
mission. ASA score was recorded for 78.0 % of these in-
dividuals, and while they were similar to those without
ASA score recorded for most characteristics, those with
ASA score recorded were more likely to have been oper-
ated on in a public hospital.
There were 3,848 individuals who had a potentially
curative surgical procedure at a public hospital in 2007
or 2008. Of these, 3,079 individuals had a record in the
Clinical Cancer Registry and 748 (24.3 %) had an
ECOG performance status recorded before their cancer
surgery. Patients with a recorded ECOG performance
status were more likely to be male, have a non-
Australian country of birth, and have a more advanced
extent of disease compared to those without ECOG
performance status.
The three measures of patient health status were not
highly correlated with one another (rASA,Charlson = 0.29,
rASA,ECOG = 0.15, rECOG,Charlson = 0.11) (Table 2).
There were 575 records with non-missing measures of
health status and other covariates that could be used in
risk adjustment comparisons. The majority had Charlson
scores of 0 (n = 502, 87.5 %) with 25 (4.4 %), 38 (6.6 %),
3 (0.5 %) and 6 (1.0 %) scoring 1,2, 3 and 4 respectively.
There were no Charlson scores higher than 4. Results of
model performance appear in Table 3. For each out-
come, the estimated intracluster correlation coefficient
was zero for all models.
Including ASA score and ECOG performance status
reduced the AIC for each outcome, but the effect was
not consistent. The AIC statistic was minimised by: the
inclusion of both measures for 365-day mortality; the in-
clusion of ASA score for extended length of stay and the
inclusion of ECOG performance status for 28-day re-
admission. Concordance was maximised by the inclusion
of both measures for all outcomes. However the max-
imum concordance for each outcome was similar to that
of the best performing models based on AIC statistics.
The effect of including ASA score and ECOG per-
formance status on the logistic regression parameter es-
timates for hospital-type is summarised in Table 4.
Changes in parameter estimates due to adjusting for dif-
ferent measures of health status were small, relative to
the parameter estimates’ standard errors, and there was
no consistent pattern in the confounding effect of ASA
score and ECOG performance status.
Discussion
Our study reports on the utility ASA score and ECOG
performance status for risk adjustment over and above
Charlson comorbidity index using routinely collected,
population-based data for NSW. The correlation be-
tween the three measures was not strong, suggesting
that the measures represent independent attributes of
patient well-being. Our study found that, for patients
Table 1 Characteristics of patients, operated on between 2007 and 2008 for cancer of the colon or rectum in NSW, Australia
Full cohort (n = 6964) Patients operated on between 2007 and 2008 in
a public hospital with a ClinCR record 01/2007 to
12/2008 (n = 3,079)
Charlson recorded
(n = 6,964, 100 %)
ASA Status recorded
(n = 5430; 78.0 %)
ASA Status missing
(n = 1534; 22.0 %)
ECOG-PS recorded
(n = 748; 24.3 %)
ECOG-PS missing
(n = 2,331; 75.7 %)
Age at admission Mean (range) 68.9 (14 to 99) 69.0 (14 to 99) 68.6 (21 to 97) 68.0 (15 to 95) 69.8 (20 to 97)
Median (IQR) 70 (61 to 78) 70 (61 to 78) 69 (61 to 78) 69 (60 to 77) 71 (62 to 79)
Sex Male 3763 (54 %) 2930 (54 %) 833 (54 %) 435 (58 %) 1241 (53 %)
Female 3201 (46 %) 2500 (46 %) 701 (46 %) 313 (42 %) 1090 (47 %)
Emergencya Non-emergency 5519 (89 %) 4353 (89 %) 1166 (91 %) 607 (86 %) 1906 (83 %)
Emergency 659 (11 %) 539 (11 %) 120 (9 %) 101 (14 %) 404 (17 %)
Country of birtha Non-Australian 1920 (28 %) 1519 (28 %) 401 (26 %) 338 (45 %) 816 (35 %)
Australian 4997 (72 %) 3876 (72 %) 1121 (74 %) 410 (55 %) 1506 (65 %)
Extent of disease Localised 2549 (37 %) 1928 (36 %) 621 (40 %) 197 (26 %) 798 (34 %)
Regional 3218 (46 %) 2544 (47 %) 674 (44 %) 387 (52 %) 1108 (48 %)
Distant 843 (12 %) 697 (13 %) 146 (10 %) 133 (18 %) 327 (14 %)
Unknown 354 (5 %) 261 (5 %) 93 (6 %) 31 (4 %) 98 (4 %)
Private hospital Public 3848 (55 %) 3202 (59 %) 646 (42 %) 748 (100 %) 2331 (100 %)
Private 3116 (45 %) 2228 (41 %) 888 (58 %)
aMissing values: Emergency status (n = 786), Country of birth (n = 47)
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with non-missing Charlson comorbidity index, ASA
score and ECOG performance status, there was no clear
optimal measure of patient-health for risk adjustment.
However, there was no clearly deficient measure. We
also found that, after including Charlson comorbidity
index, there was little to be gained by adding ASA score
or ECOG performance status when comparing outcomes
between hospital types.
Within the NSW hospital episode statistics (the
APDC), it is standard coding practice that only comor-
bid conditions which have an impact on the admission
of interest are coded. While this means that the Charl-
son scores derived from the APDC diagnosis codes are
based on conditions likely to impact outcome, it leads to
under-estimation of the prevalence of comorbid condi-
tions in the patient cohort [22]. We have previously inves-
tigated the impact of including additional comorbidity
information from previous hospital admissions in risk ad-
justment models to compare hospital cancer outcomes
[13]. This previous work demonstrated that although
Charlson scores were higher when more sources of co-
morbidity information were included, there was little
change in the performance of Charlson score in the hos-
pital risk adjustment models. Thus, for comparison of
hospital cancer outcomes, calculating the Charlson score
from comorbidity information within the index admission
was the most efficient approach, and the approach used in
this study. We acknowledge however that additional co-
morbidity information from other sources could improve
risk adjustment models in other contexts, for example to
compare individual patient outcomes.
While ASA score is reported more commonly in pub-
lic hospitals than private, patients with ASA score have
similar characteristics to those with no recorded ASA
score. The reporting of ECOG performance status how-
ever, is limited. Only a quarter of patients whose cancer
surgery was conducted in a public hospital had an
ECOG performance status recorded before their cancer
surgery. While we used the ECOG performance mea-
sured closest in time prior to cancer surgery, the ideal
would be to record ECOG close as possible to surgery,
possibly in a preoperative setting. As the analyses in this
study were necessarily restricted to a subset of patients
with colorectal cancer in NSW who were treated in a
public hospital and had complete data for Charlson,
ECOG and ASA, it is possible that these findings do not
generalise to other patient groups. This should be fur-
ther investigated in future studies.
The findings from this study regarding predictive abil-
ity agree with those from other published work. While
comorbidity (as measured by either ASA or Charlson
comorbidity index) has been demonstrated as a risk fac-
tor for poor outcomes in studies of colorectal cancer
surgery, different comorbidity indices added little to the
Table 2 Cross tabulations of Charlson, ASA and ECOG scores
(n = 575)
a)
ASA score Charlson score
0 1 2+
1 43 0 2 45
2 270 6 10 286
3 166 16 22 204
4 20 3 11 34





0 246 10 19 275
1 212 8 14 234
2 32 5 11 48
3 13 2 2 17
4 0 0 1 1
c)
ASA score ECOG
0 1 2 3 4
1 25 19 1 0 0
2 152 106 21 7 0
3 82 94 21 7 0
4 13 13 4 3 1
5 3 2 1 0 0
Table 3 Summaries of multilevel logistic regression model performance for three binary outcomes
365-day mortality Extended length of stay 28-day readmission
(Event rate: 77/575; 13.4 %) (Event rate: 92/575; 16.0 %) (Event rate: 109/575; 19.0 %)
Model AIC C AIC C AIC C
Base 396.9 0.782 472.0 0.731 572.8 0.606
Base + ASA 392.8 0.797 433.6 0.792 576.5 0.621
Base + ECOG 393.9 0.788 472.5 0.735 566.8 0.631
Base + ASA + ECOG 390.1 0.802 433.9 0.799 570.2 0.643
Base model comprises Charlson comorbidity index, age, sex, extent of cancer disease, emergency presentation and hospital type
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predictive ability regression models, [10] and yielded
strikingly similar results [11]. Similar performance of
ASA, Charlson comorbidity index and ECOG perform-
ance status was seen in a study that modelled90-day
post-surgery mortality for carcinoma of the bladder [12].
It should be noted though, that these studies were based
on data extracted from primary medical records. Recently,
cancer-specific measures of comorbidity (‘C3 indices’) de-
veloped using administrative data have been found to have
slightly improved performance compared with the
Charlson index for colorectal cancer [23]. However, the
developers conclude that the differences are so small as
to be insignificant, and that any measure of comorbid-
ity will suffice in most circumstances [23]. Consistent
with these findings, our study suggests that alternative
measures of patient health derived from administrative
data collections provide similar predictive ability.
While our study is based on population-level data
from high quality data collections, there are a number of
limitations. There were only two years of data with the
potential for ECOG performance status to be measured,
and only a small proportion of patients had ECOG per-
formance status recorded. We could not include patients
who received surgery in private hospitals, as ECOG per-
formance status was recorded in the Clinical Cancer
Registry which does not yet include private hospitals.
Those with non-missing ECOG performance status dif-
fered systematically from the entire cohort, and it is not
clear whether the same conclusions would be reached in
a more representative population. While multiple imput-
ation methods could be used to include patients with
missing data, the high proportion and likely non-
random nature of the missing ECOG data in our study
were against this approach [24]. We could not assess
thirty-day mortality, arguably a more important indica-
tor of surgical quality, in the risk adjustment models due
to the low numbers of deaths. Finally, the levels of com-
pleteness of data fields likely vary in different settings
such as the public and private sector, and within and be-
tween countries, so our findings may not generalise to
other contexts.
Conclusion
ECOG performance status has some use in risk adjust-
ment, but its routine use in population-based comparisons
of hospital outcomes cannot be recommended due to lim-
ited coverage. Coverage of ASA scores is greater than for
ECOG performance status, but there are still substantial
issues of non-reporting, particularly in private hospitals.
While predictive ability of regression models is maxi-
mised by inclusion of one or both of ASA score and
ECOG performance status, there is little to be gained by
adding ASA or ECOG to models containing the Charl-
son comorbidity index to address confounding. The
Charlson comorbidity index is an appropriate measure
to use in risk adjustment to compare outcomes between
hospitals.
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